The recalled 100 mg/25 mg losartan and potassium/hydrochlorothiazide tablets contained small amounts of N-nitrosodiethylamine, or NDEA, according to a company recall notice shared on the Food and ...

Ascendis Pharma A/S announced that its Board of Directors approved a plan to allocate approximately $25 million in the first quarter of 2025 for a share repurchase program and the net settlement ...

COPENHAGEN - Ascendis Pharma A/S (NASDAQ: ASND), a biopharmaceutical company valued at $7.15 billion, has initiated a share repurchase program, with plans to buy back up to $18.25 million of its ...

Novo Nordisk and Ascendis Pharma have partnered to develop therapies for metabolic and cardiovascular diseases, including a once-monthly GLP-1 receptor agonist that will initially target type 2 ...

The technology already has clinical and regulatory validation through two FDA-approved Ascendis products. Skytrofa, a drug for pediatric growth hormone deficiency, won its FDA nod in 2021.

So Ascendis' drug appears to be as effective as BioMarin ... So it accounted for approximately 25% of total revenues ($712 million). In this context, BioMarin's stock dropping ~17% on Monday ...

BioMarin serves that need with its CNP analog Voxzogo—the centerpiece of its growth strategy—but that drug needs to be injected once a day. Ascendis’ TransCon CNP could challenge Voxzogo.

Children treated with the Ascendis drug grew an average of 1.49 centimeters in a year relative to a placebo, achieving the primary goal of the study. BioMarin Pharmaceutical was trading lower in ...

In prisons and jails across the country, a bulky tablet enclosed in a screwed-on plastic case has become the hottest new device. Featuring limited online access, the tablets allow incarcerated ...

London: Ascendis Pharma said on Monday the U.S. Food & Drug Administration had approved its therapy to treat adult patients with a hormone disorder, sending the Danish drugmaker's shares more than ...